Last quarter (Q3 2024), Nemaura Medical's total revenue was $204.83K, an increase of 6689.13% from the same quarter last year. In Q3, Nemaura Medical's net income was $-2.16M. See Nemaura Medical’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	$ 204.83K	$ 77.04K	$ 503.91K	-	$ 0.00	$ 0.00
Cost of Revenue	-	$ 75.33K	$ 344.30K	-	-	-
Gross Profit	$ -1.27M	$ 1.72K	$ 159.61K	-	-	-
Operating Expense	$ 8.35M	$ 8.12M	$ 7.73M	$ 4.59M	$ 4.78M	$ 4.48M
Operating Income	$ -8.85M	$ -9.60M	$ -7.57M	$ -4.59M	$ -4.78M	$ -4.48M
Net Non Operating Interest Income Expense	$ -5.47M	$ -6.41M	$ -6.67M	$ -2.01M	$ 3.93K	$ 23.93K
Other Income Expense	$ -1.70M	$ 836.95K	-	$ -472.56K	-	-
Pretax Income	$ -12.63M	$ -14.14M	$ -14.49M	$ -6.12M	$ -4.77M	$ -4.45M
Tax Provision	$ -338.28K	-	$ -350.26K	$ -335.83K	$ -614.36K	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -10.62M	$ -16.84M	$ -14.14M	$ -5.79M	$ -4.16M	$ -4.45M
Basic EPS	$ -0.78	$ -0.57	$ -0.59	-	$ -0.20	$ -0.25
Diluted EPS	$ -0.78	$ -0.57	$ -0.59	$ -0.28	$ -0.20	$ -0.25
Basic Average Shares	$ 111.58M	$ 24.88M	$ 23.38M	$ 22.28M	$ 20.81M	$ 18.09M
Diluted Average Shares	$ 111.58M	$ 24.88M	$ 23.38M	$ 22.28M	$ 20.81M	$ 18.09M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 8.35M	$ 8.19M	$ 8.07M	$ 4.59M	$ 4.78M	$ 4.48M
Net Income From Continuing And Discontinued Operation	$ -10.34M	$ -14.14M	$ -14.14M	$ -5.79M	$ -4.16M	$ -4.45M
Normalized Income	$ -13.95M	$ -9.36M	-	-	$ -4.16M	$ -4.45M
Interest Expense	-	-	-	-	-	-
EBIT	$ -7.16M	$ -7.73M	$ -7.83M	$ -4.11M	$ -4.78M	$ -4.48M
EBITDA	$ -7.15M	$ -5.42M	$ -931.88K	$ -4.02M	$ -4.72M	$ -4.44M

Currency in USD

Nemaura Medical Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing